Eprotirome

Drug Profile

Eprotirome

Alternative Names: KB2115

Latest Information Update: 21 Dec 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Karo Bio
  • Class Anilides; Antihyperlipidaemics; Obesity therapies; Small molecules
  • Mechanism of Action Thyroid hormone receptor beta agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Dyslipidaemias; Hypercholesterolaemia; Obesity

Most Recent Events

  • 14 Feb 2012 Discontinued - Phase-II for Dyslipidaemias in Finland (PO)
  • 14 Feb 2012 Discontinued - Phase-III for Hypercholesterolaemia in Sweden (PO)
  • 04 Oct 2011 Phase-III clinical trials in Hypercholesterolaemia in Sweden (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top